Verismo Secures CLDN6 Target, Expands Solid Tumor CAR-T Pipeline
Second Targeted Binder Secured through Collaboration with UPenn
Initiation of Preclinical Development for CLDN6 Using KIR-CAR Platform
Expansion of Solid Tumor Indications Following Mesothelin
HLB Innovation's U.S. subsidiary, Verismo Therapeutics, announced on July 21 that it has secured a novel solid tumor-targeted binder through research collaboration with the University of Pennsylvania (UPenn) and will expand its next-generation KIR-CAR platform-based solid tumor pipeline.
Verismo has applied a targeted binder that recognizes claudin 6 (CLDN6) antigens on the surface of cancer cells to its KIR-CAR platform, initiating preclinical development targeting solid tumors that express CLDN6.
This CLDN6-targeted binder was discovered by the research team of Dr. Donald Siegel, co-founder and co-chair of the Scientific Advisory Board at UPenn’s Perelman School of Medicine, through a research support agreement with Verismo. It is the second targeted binder secured through collaboration with UPenn, following the DS191 applied to the hematological cancer CAR-T candidate 'SynKIR-310,' which is currently in phase 1 clinical trials.
CLDN6 is known to be expressed in various types of cancer but is limited in expression in normal adult tissue, making it an attractive emerging target for next-generation immuno-oncology therapies. Development is also underway for various therapeutic approaches such as CAR-T, antibody-drug conjugate (ADC), and bispecific antibodies.
Verismo plans to combine its proprietary CLDN6 binder with the multi-chain KIR-CAR platform to overcome the persistence limitations of existing CLDN6-targeted therapies and to develop cell therapies that improve anti-cancer immune responses in solid tumors.
Brian Kim, CEO of Verismo, stated, "Securing CLDN6 as a new target for solid tumors expands the application scope of the KIR-CAR platform," adding, "We will continue to broaden our pipeline to target a variety of solid tumors."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Verismo is currently conducting phase 1 clinical trials in the United States for the solid tumor CAR-T candidate 'SynKIR-110' and the hematological cancer CAR-T candidate 'SynKIR-310.' According to the company, initial interim results from SynKIR-110 were presented at the American Association for Cancer Research (AACR) conference in April, confirming safety and early signals of tumor reduction in the first three dose cohorts.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.